TRAVERSE Bone Fracture Substudy Cost, Cost-Effectiveness, and Health-Economic Implications

At a glance

Parameter	Detail
Trial	TRAVERSE Bone Fracture Substudy
N	5,246
Intervention	Transdermal testosterone 1.62% gel (AndroGel)
Comparator	Matching placebo gel
Duration	Median 3.19 years
Primary endpoint	Incidence of clinical fractures
Key result	HR 1.43 (95% CI 1.04, 1.97); 7.0% vs 4.9% fracture incidence

The Fracture Signal That Rewrites TRT Economics

Before TRAVERSE, the economic case for testosterone replacement in older men with age-related hypogonadism rested on a simple logic chain: low testosterone correlates with low bone mineral density (BMD), TRT raises BMD, and higher BMD should reduce fractures. The TRAVERSE bone fracture substudy broke that chain. Among 5,246 men aged 45 to 80 with hypogonadism and established or high cardiovascular risk, testosterone gel produced a statistically significant 43% increase in clinical fractures compared to placebo (HR 1.43; 95% CI 1.04, 1.97).

This result was not predicted by earlier BMD-focused trials. The Testosterone Trials (TTrials) had shown a 6.2% increase in volumetric BMD at the spine over 12 months. Clinicians and payers had reasonably assumed that fracture reduction would follow. TRAVERSE demonstrated that BMD is not a reliable surrogate for fracture outcomes in this context, a finding that fundamentally changes the cost-effectiveness arithmetic.

Why No Formal CEA Exists Yet

As of mid-2026, no published cost-effectiveness analysis (CEA) specifically models the TRAVERSE fracture data. Several reasons explain the gap. TRAVERSE was designed as a cardiovascular safety trial, not a health-economic study, so utility weights and resource-use data were not prospectively collected. The fracture substudy was pre-specified but secondary, and the absolute event rates (7.0% vs 4.9% over 3.2 years) yield a number needed to harm (NNH) of approximately 48, a signal large enough to matter clinically but modest enough that modelers need to make assumptions about fracture type distributions and downstream costs.

What we can do is construct a structured cost framework using TRAVERSE clinical data, published fracture cost literature, and current testosterone pricing. The framework below synthesizes these inputs.

HealthRX.com Cost-Impact Framework: TRAVERSE Fracture Economics

Component 1: Drug Acquisition Costs

Testosterone gel 1.62% (branded AndroGel) carried a wholesale acquisition cost (WAC) of roughly $580 per month at the time of enrollment. Generic topical testosterone formulations are now available at $30 to $90 per month depending on pharmacy and formulation. Injectable testosterone cypionate, the most common alternative, costs $20 to $50 per month at generic pricing.

For a 3.2-year treatment course matching TRAVERSE duration:

The wide spread between branded and generic is critical. Any CEA using branded pricing will produce far worse value ratios than one using current generic pricing. Most commercial payers now mandate generic substitution, making the $2,300 figure the more policy-relevant estimate.

Component 2: Incremental Fracture Costs

The TRAVERSE substudy reported that the excess fracture rate attributable to testosterone was approximately 2.1 percentage points over 3.2 years (7.0% minus 4.9%). Fractures in this trial were predominantly non-vertebral. Using published U.S. fracture cost data:

If we assume a weighted average cost of $18,000 per incident fracture (reflecting the trial's non-hip-predominant fracture mix), then for every 1,000 men treated with testosterone for 3.2 years, roughly 21 excess fractures would occur, generating approximately $378,000 in additional fracture-related costs, or $378 per treated patient.

Component 3: QALY Decrements From Fractures

Each clinical fracture carries a quality-of-life penalty. Published utility decrements range from 0.04 to 0.05 QALYs for a wrist fracture to 0.15 to 0.20 QALYs for a hip fracture in the first year post-event. Using a blended estimate of 0.08 QALYs lost per fracture (weighted toward the non-hip distribution seen in TRAVERSE), the 21 excess fractures per 1,000 patients translate to a loss of approximately 1.68 QALYs per 1,000 patients, or 0.0017 QALYs per treated patient.

Component 4: Offsetting Benefits (The Incomplete Ledger)

TRT produces measurable benefits in sexual function, energy, and mood, effects confirmed in the TTrials program. The sexual function benefit in TTrials had a standardized effect size of about 0.45 over 12 months. Translating these into QALYs is difficult because validated utility weights for "improved libido in a 65-year-old" do not exist in standard catalogs.

Published estimates from European health technology assessments place the QALY gain from TRT symptom relief at 0.01 to 0.03 per year, or roughly 0.03 to 0.10 over a 3.2-year horizon. Even at the upper bound of 0.10 QALYs gained per patient, the fracture-related QALY loss (0.0017 per patient) appears small in comparison at the individual level. But this comparison is misleading because it ignores the cost side of the ratio. The question is not whether benefits exceed harms in isolation but whether the incremental cost-effectiveness ratio (ICER) falls below the willingness-to-pay threshold.

Component 5: Illustrative ICER Calculation

For generic testosterone gel over 3.2 years:

• Drug cost: $2,300
• Monitoring (labs, visits): ~$1,200
• Incremental fracture costs: $378
• Total incremental cost per patient: ~$3,878
• Net QALY gain (symptom benefit minus fracture decrement): 0.03 to 0.098
• Estimated ICER: $39,600 to $129,300 per QALY

At the commonly cited $100,000/QALY threshold, TRT may or may not be cost-effective depending entirely on how large the symptom-relief QALY gain truly is. If symptom benefit is at the lower bound (0.03 QALYs), the ICER exceeds $129,000/QALY, a poor value proposition. At the upper bound, it approaches borderline acceptability.

With branded gel pricing, the ICER exceeds $230,000/QALY under any reasonable assumption. This explains why virtually all payers now require generic formulations.

Payer-Coverage Implications

Prior Authorization Tightening

The FDA's 2015 label update for testosterone products already restricted the approved indication to men with documented hypogonadism due to specific medical conditions (testicular disorders, pituitary disease), not age-related decline. TRAVERSE's cardiovascular and fracture data have given pharmacy benefit managers additional justification to enforce strict prior authorization criteria.

Current coverage patterns among large commercial payers:

• Step therapy: most plans require trial of injectable testosterone cypionate before covering gels
• Lab documentation: two morning total testosterone levels <300 ng/dL, plus an identified organic cause
• Age restrictions: some Medicare Advantage plans have added utilization review flags for men over 65, citing TRAVERSE fracture data
• Duration limits: select plans cap initial authorization at 6 to 12 months with re-evaluation

Medicare Part D Considerations

Testosterone products are covered under Medicare Part D. The TRAVERSE primary cardiovascular results (non-inferiority to placebo for MACE) removed one coverage barrier, but the fracture signal introduces a new one. CMS has not issued a National Coverage Determination specific to testosterone and fracture risk. Individual Part D plans retain discretion, and several have added fracture risk screening requirements.

The Individual Patient Value Calculation

For a clinician and patient making a shared decision, the economic question collapses to a personal risk-benefit ratio that insurance formulary math cannot fully capture. The TRAVERSE bone substudy gives the following anchors:

Absolute risk increase: 2.1 percentage points over 3.2 years (NNH ≈ 48). One additional man will fracture for every 48 treated. The other 47 experience no skeletal harm.

Who might bear the most risk: men with pre-existing osteopenia, those on glucocorticoids, heavy alcohol users, and men with a prior fragility fracture. TRAVERSE did not power subgroup analyses by baseline BMD, so these risk modifiers are extrapolated from general osteoporosis literature.

Who gets the most benefit: men with severe, symptomatic hypogonadism (total testosterone consistently <200 ng/dL) and disabling sexual dysfunction or profound fatigue. The Endocrine Society 2018 guidelines recommend TRT only for men with unequivocally low testosterone and clear symptoms, a recommendation that TRAVERSE reinforces rather than overturns.

Out-of-pocket cost: for a man on generic injectable testosterone cypionate with commercial insurance, monthly cost is typically $10 to $30 after copay. The financial barrier is low. The economic question at the patient level is less about drug cost and more about the potential downstream cost of a fracture: lost wages, rehabilitation, possible surgery, and reduced independence.

Limitations of Any Economic Modeling From TRAVERSE

Several constraints make formal CEA from TRAVERSE data provisional at best:

1. Fracture types were heterogeneous. The substudy did not report hip fractures separately in sufficient numbers to model high-cost fracture events reliably.
2. No prospective utility data. Patient-reported quality-of-life instruments (EQ-5D, SF-6D) were not collected for the fracture substudy.
3. The fracture signal is biologically unexplained. Without a confirmed mechanism (cortical bone thinning via estrogen-receptor effects, increased fall risk from hematocrit-related dizziness, or another pathway), modelers cannot predict whether the signal will replicate in younger or healthier populations.
4. Generic pricing changes rapidly. Any ICER calculated today may shift within 12 to 18 months as market dynamics evolve.
5. Comparator matters. TRAVERSE compared testosterone to placebo, not to other treatments for hypogonadal symptoms (e.g., clomiphene citrate off-label). A true cost-effectiveness comparison would include active alternatives.

What Comes Next

Two developments could clarify the economics. First, a formal CEA using TRAVERSE patient-level data with imputed utilities would produce more defensible ICERs than the framework above. Second, ongoing post-marketing surveillance may establish whether fracture risk is dose-dependent or limited to certain testosterone formulations, information that would allow payers to design smarter formulary restrictions rather than blanket denials.

Until those data arrive, the TRAVERSE fracture signal functions as a cost multiplier that pushes TRT's economic profile from "potentially cost-effective for symptomatic men" toward "uncertain value requiring careful patient selection." For payers, this means tighter utilization management is economically rational. For patients and clinicians, it means the conversation about TRT must now include fracture risk as a line item, not just cardiovascular safety and symptom relief.

Frequently asked questions

›Has anyone published a formal cost-effectiveness analysis of TRT using TRAVERSE fracture data?

No peer-reviewed CEA incorporating the TRAVERSE bone fracture substudy results has been published as of mid-2026. Prior TRT economic models (most from European HTA bodies) used BMD as a surrogate and assumed fracture reduction, assumptions that TRAVERSE invalidated.

›How much does testosterone replacement therapy cost per month?

Generic testosterone cypionate injections cost $20 to $50 per month. Generic topical gels run $30 to $90. Branded AndroGel at wholesale exceeds $500 monthly. Most insurance plans require generic substitution, keeping patient out-of-pocket costs under $30 per month with commercial coverage.

›What is the number needed to harm for fractures in TRAVERSE?

Approximately 48. For every 48 men treated with testosterone gel for 3.2 years, one additional clinical fracture occurred compared to placebo, based on the absolute risk difference of 2.1 percentage points.

›Does Medicare cover testosterone replacement therapy?

Yes, testosterone products are covered under Medicare Part D with prior authorization. Coverage requires documented hypogonadism with two low morning testosterone levels and an identified medical cause. Some Medicare Advantage plans have added utilization review based on TRAVERSE safety data.

›How does the fracture risk change the cost per QALY of TRT?

Using generic gel pricing and conservative estimates, the ICER ranges from roughly $40,000 to $130,000 per QALY depending on the assumed magnitude of symptom-relief benefit. Adding fracture costs worsens the ratio by approximately $4,000 to $12,000 per QALY compared to models that ignore skeletal harm.

›Are injectable testosterone formulations safer for bones than gels?

TRAVERSE used only transdermal gel. No RCT has compared fracture outcomes between injectable and topical testosterone. Injectables produce higher peak serum levels and greater aromatization to estradiol, which could theoretically differ in skeletal effects, but this remains speculative.

›Did the FDA update testosterone labels after the TRAVERSE fracture findings?

The FDA's existing testosterone labeling already restricts the indication to pathologic hypogonadism and warns of cardiovascular risk. As of mid-2026, no specific label revision addresses the TRAVERSE fracture signal, though an advisory committee review remains possible.

›Should men on TRT get bone density screening?

The Endocrine Society guidelines recommend baseline DXA for men with risk factors for osteoporosis starting TRT. Given the TRAVERSE fracture data, periodic DXA monitoring (every 1 to 2 years) during TRT is a reasonable clinical practice, though no guideline has formally updated to mandate it based on this substudy.

›What is the biggest limitation of modeling cost-effectiveness from TRAVERSE?

The absence of prospectively collected quality-of-life data. Without EQ-5D or SF-6D scores from trial participants, any QALY estimates rely on external utility mappings that may not reflect the actual experience of older hypogonadal men with cardiovascular comorbidities.

›Could the fracture signal be a statistical fluke?

The confidence interval (HR 1.04, 1.97) just excludes 1.0, and the substudy was not independently powered for fracture as a primary outcome. A chance finding cannot be ruled out, but the consistent direction of effect across fracture sites and the large sample (N = 5,246) argue against dismissing it entirely.

References

1. Snyder PJ, et al. Testosterone treatment and fractures in men with hypogonadism. N Engl J Med. 2024;390(3):203-211. PubMed
2. Lincoff AM, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107-117. PubMed
3. Snyder PJ, et al. Effects of testosterone treatment in older men. N Engl J Med. 2016;374(7):611-624. PubMed
4. Bhasin S, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. PubMed
5. FDA Drug Safety Communication: testosterone products and cardiovascular risk. U.S. Food and Drug Administration. FDA.gov
6. Snyder PJ, et al. Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone. JAMA Intern Med. 2017;177(4):471-479. PubMed